Flush with a $164M raise, Cel­lec­tis ups its bet on CAR-T and gene edit­ing pro­grams

With new part­ners at Al­lo­gene Ther­a­peu­tics, Cel­lec­tis $CLLS is ready to hus­tle its off-the-shelf CAR-T ther­a­pies to the mar­ket — tak­ing ad­van­tage of $164 mil­lion it’s just raised from a pub­lic of­fer­ing.

The Paris-based biotech spelled out the in­tend­ed us­es of the pro­ceeds in an SEC fil­ing, al­lo­cat­ing $100 mil­lion to es­tab­lish com­mer­cial ca­pa­bil­i­ties for its cur­rent im­muno-on­col­o­gy can­di­dates, $20 mil­lion for an ad­di­tion­al UCART prod­uct can­di­date, and $30 mil­lion to pur­sue a non-on­col­o­gy ap­pli­ca­tion of its gene edit­ing tech­nol­o­gy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER